[go: up one dir, main page]

PE135299A1 - Derivados de 1,3,8-triaza-espiro[4,5]decan-4-ona - Google Patents

Derivados de 1,3,8-triaza-espiro[4,5]decan-4-ona

Info

Publication number
PE135299A1
PE135299A1 PE1998001176A PE00117698A PE135299A1 PE 135299 A1 PE135299 A1 PE 135299A1 PE 1998001176 A PE1998001176 A PE 1998001176A PE 00117698 A PE00117698 A PE 00117698A PE 135299 A1 PE135299 A1 PE 135299A1
Authority
PE
Peru
Prior art keywords
alkyl
phenyl
espiro
triaza
decan
Prior art date
Application number
PE1998001176A
Other languages
English (en)
Inventor
Andrea Cesura
Geo Adam
Guido Galley
Stephan Rover
Jurgen Wichmann
Francois Jenck
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE135299A1 publication Critical patent/PE135299A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
  • Color Printing (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A COMPUESTOS DE FORMULA I; R1 ES H, ALQUILO, HALOGENO, ALCOXI, TRIFLUOROMETILO, ALQUIL-FENILO, CICLOALQUILO C5-C7; R2 ES H, ALQUILO, FENILO, ALQUIL-FENILO; R3 ES H, ALQUILO, BENCILO, ALQUIL-FENILO, ALQUILDIFENILO, ENTRE OTROS; R4 ES H, ALQUILO o NITRILO; "A" ES UN CICLOALQUILO C5-C15 OPCIONALMENTE SUSTITUIDO, UN GRUPO b, c, d, ENTRE OTROS; R5 Y R6 SON H, ALQUILO O FORMAN JUNTOS UN FENILO; R7 ES H, ALQUILO; n ES 1-4. SON COMPUESTOS PREFERIDOS 8-(DECAHIDRONAFTALEN-2-IL)-1-FENIL-1,3,8-TRIAZA-ESPIRO-[4,5]-DECAN-4-ONA, 8-(CIS-OCTAHIDROINDEN-2-IL)-1-FENIL-1,3,8-TRIAZA-ESPIRO[4.5]DECAN-4-ONA, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. EL COMPUESTO I ES UN AGONISTA O ANTAGONISTA DEL RECEPTOR DE ORFANINA FQ (OFQ) POR LO QUE PUEDE SER UTIL PARA EL TRATAMIENTO DE DEFICITS DE MEMORIA Y ATENCION, TRASTORNOS PSIQUIATRICOS, NEUROLOGICOS Y PSICOLOGICOS TAL COMO TRASTORNOS DE ANSIEDAD, ESTRES, DEPRESION, TRAUMA, PERDIDA DE LA MEMORIA, ENFERMEDAD DE ALZHEIMER, EPILEPSIA, CONVULSIONES
PE1998001176A 1997-12-05 1998-12-03 Derivados de 1,3,8-triaza-espiro[4,5]decan-4-ona PE135299A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97121427 1997-12-05

Publications (1)

Publication Number Publication Date
PE135299A1 true PE135299A1 (es) 2000-01-18

Family

ID=8227753

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998001176A PE135299A1 (es) 1997-12-05 1998-12-03 Derivados de 1,3,8-triaza-espiro[4,5]decan-4-ona

Country Status (29)

Country Link
US (1) US6043366A (es)
JP (1) JP3366868B2 (es)
KR (1) KR19990062800A (es)
CN (1) CN1118467C (es)
AR (1) AR016428A1 (es)
AT (1) ATE212635T1 (es)
AU (1) AU744338B2 (es)
BR (1) BR9805297B1 (es)
CA (1) CA2255171C (es)
CO (1) CO4990965A1 (es)
CZ (1) CZ399698A3 (es)
DE (1) DE69803653T2 (es)
DK (1) DK0921125T3 (es)
ES (1) ES2170446T3 (es)
HR (1) HRP980613A2 (es)
HU (1) HUP9802807A3 (es)
ID (1) ID21413A (es)
IL (1) IL127399A0 (es)
MA (1) MA26573A1 (es)
NO (1) NO312161B1 (es)
NZ (1) NZ333159A (es)
PE (1) PE135299A1 (es)
PL (1) PL330062A1 (es)
PT (1) PT921125E (es)
SG (1) SG71173A1 (es)
TR (1) TR199802520A3 (es)
TW (1) TW408123B (es)
YU (1) YU55198A (es)
ZA (1) ZA9811128B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2237047T3 (es) * 1998-10-23 2005-07-16 Pfizer Inc. Compuestos de 1,3,8-triazaespiro(4,5)decanona como agonistas del receptor orl1.
EP1537110B1 (en) * 1999-12-06 2007-01-17 Euro-Celtique, S.A. Triazospiro compounds having nociceptin receptor affinity
CA2454785C (en) * 2001-07-23 2010-09-07 Banyu Pharmaceutical Co., Ltd. 4-oxoimidazolidine-2-spiropiperidine derivatives
JP4056977B2 (ja) 2002-03-29 2008-03-05 田辺三菱製薬株式会社 睡眠障害治療薬
CA2498275C (en) * 2002-09-09 2011-07-12 Janssen Pharmaceutica, N.V. Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1 receptor mediated disorders
AU2003299791A1 (en) * 2002-12-20 2004-07-22 Bayer Pharmaceuticals Corporation Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
US20080287478A1 (en) * 2003-05-23 2008-11-20 Lars Bo Laurenborg Hansen Nociceptin Analogues and Uses Thereof
RU2006117368A (ru) * 2003-10-23 2007-12-10 Ф.Хоффманн-Ля Рош Аг (Ch) Производные триазаспиропипередина, предназначенные для применения в качестве ингибиторов glyt-1 при лечении неврологических и психоневрологических нарушений
US20060178390A1 (en) * 2004-08-02 2006-08-10 Alfonzo Jordan 1,3,8-Triazaspiro[4,5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
MX2007011546A (es) * 2005-03-22 2007-10-19 Hoffmann La Roche Nueva sal y polimorfos del inhibidor de dipeptidil-peptidasa iv.
JP2009541342A (ja) * 2006-06-20 2009-11-26 ワイス Kv1.5カリウムチャネル阻害剤
EP2102206B1 (en) * 2006-11-28 2015-04-08 Janssen Pharmaceutica NV Salts of 3-(3-amino-2-(r)-hydroxy-propyl)-1-(4-fluoro-phenyl)-8-(8-methyl-naphthalen-1-ylmethyl)-1,3,8-triaza-spiro[4.5]decan-4-one
ES2541133T3 (es) 2007-03-01 2015-07-16 Mitsubishi Tanabe Pharma Corporation Compuesto de bencimidazol y uso farmacéutico del mismo
JP5490677B2 (ja) * 2007-04-09 2014-05-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 不安及び鬱病の処置のためのorl−1受容体リガンドとしての1,3,8−三置換−1,3,8−トリアザ−スピロ[4.5]デカン−4−オン誘導体
PA8801401A1 (es) * 2007-10-25 2009-05-15 Janssen Pharmaceutica Nv Arilindenopirimidinas y su uso como adenosina a2a
TW201016675A (en) * 2008-09-16 2010-05-01 Mitsubishi Tanabe Pharma Corp Crystalline benzoimidazole compound and salt thereof
US20100076003A1 (en) * 2008-09-19 2010-03-25 Kathleen Battista 5-oxazolidin-2-one substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful as orl-1 receptor modulators
WO2010037081A1 (en) * 2008-09-29 2010-04-01 Palatin Technologies, Inc. Melanocortin receptor-specific spiro-piperidine compounds
CN102459278A (zh) 2009-06-16 2012-05-16 默沙东公司 取代的-1,3,8-三氮杂螺[4.5]癸烷-2,4-二酮
JP7002335B2 (ja) * 2015-07-03 2022-01-20 エフ.ホフマン-ラ ロシュ アーゲー Ddr1阻害剤としてのトリアザ-スピロデカノン

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155669A (en) * 1962-06-22 1964-11-03 Res Lab Dr C Janssen N V 2, 4, 8-triaza-spiro (4, 5) dec-2-enes
US3161644A (en) * 1962-06-22 1964-12-15 Res Lab Dr C Janssen N V 1-benzyl-4-substituted piperidines
US3155670A (en) * 1962-06-22 1964-11-03 Res Lab Dr C Janssen N V 1-oxo-2, 4, 8, triaza-spiro (4, 5) decanes
US3238216A (en) * 1963-06-20 1966-03-01 Res Lab Dr C Janssen N V Substituted 1, 3, 8-triaza-spiro (4, 5) decanes
GB1486546A (en) * 1975-02-28 1977-09-21 Yoshitomo Pharma Ind Ltd 4,4-diphenyl-cyclohexylpiperidine compounds and analogues thereof
JPS51100084A (es) * 1975-02-28 1976-09-03 Yoshitomi Pharmaceutical
JPS5212171A (en) * 1975-07-17 1977-01-29 Yoshitomi Pharmaceut Ind Ltd Process for preparation of cyclohexane derivatives
JPS5934713B2 (ja) * 1976-01-05 1984-08-24 ウェルファイド株式会社 脂環式誘導体
US4076821A (en) * 1976-02-27 1978-02-28 Yoshitomi Pharmaceutical Industries, Ltd. 4,4-Diphenylcycloalkylpiperidines and psychotropic compositions thereof
MA19091A1 (fr) * 1980-03-10 1981-10-01 Janssen Pharmaceutica Nv Nouveaux derives de i-(4-aryl-cyclohexyl)piperidine .
US4329353A (en) * 1980-10-22 1982-05-11 Janssen Pharmaceutica, N.V. 1-(4-Aryl-cyclohexyl)piperidine derivatives, method of use thereof and pharmaceutical compositions thereof
GR73633B (es) * 1980-03-10 1984-03-26 Janssen Pharmaceutica Nv
ATE67769T1 (de) * 1983-01-25 1991-10-15 Ciba Geigy Ag Neue peptidderivate.
JPS6012357B2 (ja) * 1984-01-23 1985-04-01 吉富製薬株式会社 脂環式誘導体
CA2226058C (en) * 1997-01-30 2008-01-29 F. Hoffmann-La Roche Ag 8-substituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives

Also Published As

Publication number Publication date
CA2255171A1 (en) 1999-06-05
ZA9811128B (en) 1999-06-07
NO312161B1 (no) 2002-04-02
DE69803653T2 (de) 2002-08-29
JP3366868B2 (ja) 2003-01-14
IL127399A0 (en) 1999-10-28
ATE212635T1 (de) 2002-02-15
BR9805297A (pt) 2000-02-01
CZ399698A3 (cs) 1999-06-16
JPH11228575A (ja) 1999-08-24
NO985684L (no) 1999-06-07
PT921125E (pt) 2002-06-28
ES2170446T3 (es) 2002-08-01
AU744338B2 (en) 2002-02-21
BR9805297B1 (pt) 2010-07-13
AU9608798A (en) 1999-06-24
HUP9802807A3 (en) 2000-01-28
MA26573A1 (fr) 2004-12-20
ID21413A (id) 1999-06-10
CO4990965A1 (es) 2000-12-26
CN1222521A (zh) 1999-07-14
AR016428A1 (es) 2001-07-04
HRP980613A2 (en) 1999-08-31
TR199802520A2 (xx) 1999-06-21
HUP9802807A2 (hu) 1999-08-30
DE69803653D1 (de) 2002-03-14
PL330062A1 (en) 1999-06-07
TR199802520A3 (tr) 1999-06-21
TW408123B (en) 2000-10-11
DK0921125T3 (da) 2002-05-13
NO985684D0 (no) 1998-12-04
YU55198A (sh) 2001-12-26
HU9802807D0 (en) 1999-02-01
SG71173A1 (en) 2000-03-21
KR19990062800A (ko) 1999-07-26
NZ333159A (en) 2000-06-23
CN1118467C (zh) 2003-08-20
CA2255171C (en) 2009-09-29
US6043366A (en) 2000-03-28

Similar Documents

Publication Publication Date Title
PE135299A1 (es) Derivados de 1,3,8-triaza-espiro[4,5]decan-4-ona
AR016129A1 (es) Compuestos derivados de 5h-tiazolo[3,2-a]pirimidina; su uso, un procedimiento para prepararlos, medicamentos que los contienen y compuestos utiles comointermediarios
PT98393A (pt) Processo para a preparacao de derivados de quinuclidina
PE20000728A1 (es) Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda
PE20010467A1 (es) 1,2,4,5-tetrahidro-benzo[d]azepin como antagonista del receptor metabotropico de glutamato
MY126586A (en) Carbamic acid derivatives and their use as metabotropic glutamate receptor ligands
PE97799A1 (es) Derivados de piridina
PE20020721A1 (es) Derivados de quinuclidina como agentes antimuscarinicos m3
GR3034396T3 (en) 1-piperazino-1,2-dihydroindene derivatives.
OA09579A (en) Certain imidazoquinoxalines a new class of gaba brain receptor ligands
PE59999A1 (es) Derivados de 1,3,8-triaza-espiro[4,5]decan-4-ona-8-sustituidos
ES2113081T3 (es) 1,4-benzotiazepinas utiles como agentes neurologicos.
PE20011114A1 (es) Decahidro-isoquinolinas
UY24482A1 (es) Quinoxalinadionas
BG104192A (en) Substituted 4-oxo-naphthyridine-3-carboxamides as gaba brain receptor ligands
CO4900047A1 (es) Amidas del acido 4-(n -benzoilamino)-penten-2-enoico que tienen actividad como antagonistas de neuroquinina
YU26499A (sh) Derivati diaza-spiro/3,5/nonana
KR920018030A (ko) 치환된 이미다졸-2-온의 유도체 및 이의 제조방법
PT99864A (pt) Processo para a preparacao de novas composicoes farmaceuticas contendo antagonistas de receptor de quisqualato
DE69526452D1 (de) Indolditerpen alkaloide
CA2601098A1 (en) Dipyrazoles as central nervous system agents
BRPI0410613A (pt) preparação de quinoxalinas substituìdas a partir da dianlina com 2,3-diidróxi-1,4-dioxano
ATE214384T1 (de) Anticonvulsive aminosäure-derivate
RU2002132883A (ru) Новые полициклические инданилимидазолы, обладающие альфа2 адренергической активностью
MX9703671A (es) Compuesto de aminometil arilo y ligandos selectivos del subtipo de receptor de la dopamina.

Legal Events

Date Code Title Description
FC Refusal